Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65 Andro Settlements Include “Corrective Advertising” Provision

This article was originally published in The Tan Sheet

Executive Summary

Settling defendants in California's Prop 65 litigation against androstenedione supplement marketers would pay from $1,341 to $4,546 each to fund "corrective advertising" programs, according to proposed consent judgments filed in Oakland state court

You may also be interested in...



Prop 65 Steroid Suit Planned Against Supplements Named In Post

The Center for Environmental Health plans to file a Prop 65 suit in January against 19 dietary supplement manufacturers and retailers for selling products containing anabolic steroids without warning labels, the group announces in a recent notice letter

Prop 65 Steroid Suit Planned Against Supplements Named In Post

The Center for Environmental Health plans to file a Prop 65 suit in January against 19 dietary supplement manufacturers and retailers for selling products containing anabolic steroids without warning labels, the group announces in a recent notice letter

Prop 65 Steroid Suit Planned Against Supplements Named In Post

The Center for Environmental Health plans to file a Prop 65 suit in January against 19 dietary supplement manufacturers and retailers for selling products containing anabolic steroids without warning labels, the group announces in a recent notice letter

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel